Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -258.92% is 63% above its 5-year average of -708.16%, near the high end of its 5-year range (-3778.38%–-45.82%).
17.89% above its 12-month average of -315.35%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -92.65%.
EBITDA MARGIN
-258.92%
EBITDA MARGIN AVG TTM
-315.35%
EBITDA MARGIN AVG 3Y
-258.46%
EBITDA MARGIN AVG 5Y
-708.16%
EBITDA MARGIN AVG 10Y
-616.14%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+17.89%
CURRENT VS 3Y AVG
-0.18%
CURRENT VS 5Y AVG
+63.44%
CURRENT VS 10Y AVG
+57.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ProQR Therapeutics N.V.
Market Cap
$173.76M
EBITDA Margin
-258.92%
TTM Avg
-315.35%
3Y Avg
-258.46%
5Y Avg
-708.16%
Market Cap
$172.51M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$172.29M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
Market Cap
$175.46M
EBITDA Margin
-6455.53%
TTM Avg
-6455.53%
3Y Avg
-6455.53%
5Y Avg
-6455.53%
Market Cap
$171.44M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$178.36M
EBITDA Margin
-5219.12%
TTM Avg
-6964.15%
3Y Avg
-7000.85%
5Y Avg
-5161.09%
Market Cap
$169.85M
EBITDA Margin
14.71%
TTM Avg
8.99%
3Y Avg
8.81%
5Y Avg
10.76%
Market Cap
$168.66M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$167.77M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProQR Therapeutics N.V. (PRQR) | $173.76M | -258.92% | -315.35% | -258.46% | -708.16% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.51M | -144.16% | -87.79% | -115.19% | -149.65% |
| Journey Medical Corporation (DERM)vs › | $172.29M | -6.19% | -12.15% | -13.37% | -13.97% |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.46M | -6455.53% | -6455.53% | -6455.53% | -6455.53% |
| Cue Biopharma, Inc. (CUE)vs › | $171.44M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Yarrow Bioscience Inc (YARW)vs › | $178.36M | -5219.12% | -6964.15% | -7000.85% | -5161.09% |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | 14.71% | 8.99% | 8.81% | 10.76% |
| MediWound Ltd. (MDWD)vs › | $168.66M | -138.09% | -113.30% | -81.67% | -67.39% |
| Nkarta, Inc. (NKTX)vs › | $167.77M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.63M | -748.35% | -748.35% | -1092.82% | -1042.94% |
Gross Margin
83.0%
EBITDA Margin
-258.9%
Operating Margin
-275.9%
Net Margin
-229.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -92.65% |
| 2026-03-31 | -637.24% |
| 2025-12-31 | -179.56% |
| 2025-09-30 | -364.08% |
| 2025-06-30 | -303.22% |
| 2025-03-31 | -224.34% |
| 2024-12-31 | -218.48% |
| 2024-09-30 | -208.90% |
| 2024-06-30 | -45.82% |
| 2024-03-31 | -165.93% |
| 2023-12-31 | -168.70% |
| 2023-09-30 | -492.63% |
| 2023-06-30 | -661.06% |
| 2023-03-31 | -1268.29% |
| 2022-12-31 | -1012.72% |
| 2022-09-30 | -2163.40% |
| 2022-06-30 | -1481.15% |
| 2022-03-31 | -1338.26% |
| 2021-12-31 | -3778.38% |
| 2021-09-30 | -1210.10% |
| 2021-06-30 | -1926.76% |
| 2018-12-31 | -254.64% |
| 2017-12-31 | 684.57% |
| 2016-12-31 | -437.77% |
| 2015-12-31 | -78.59% |
| 2014-12-31 | -1585.76% |
